Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

The once- and twice-daily GLP-1 RAs are now well established for their ... It has similar efficacy to other GLP1 agonists, with seemingly lower incidence of nausea. Another important distinction ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

GLP-1 agonist medications have gained significant attention, especially for their role in weight management and type 2 diabetes treatment. While these medications have been around for nearly 20 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

The category is expected to scale to $8.7 billion by 2027. The market for GLP-1 agonist drugs also continues to grow and is expected to exceed $100 billion by 2030. NBJ's report aims to educate ...